Director/PDMR Shareholding

RNS Number : 8156A

Kromek Group PLC

29 March 2017

 

29 March 2017

Kromek Group plc

("Kromek" or the "Company")

Director/PDMR Shareholding

Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces that it has received notification that, on 24 March 2017,  Berry Beumer, Chief Operating Officer of Kromek, purchased 80,000 Ordinary Shares of 1 pence each ("Ordinary Shares") in the Company at a price of 29.35 pence per share.

Following the purchase, Mr. Beumer has an interest in 80,000 Ordinary Shares representing 0.03% of the entire current issued share capital of the Company.

Enquiries

Kromek Group plc	01740 626 060
Arnab Basu, CEO Derek Bulmer, CFO
Cenkos Securities plc	0207 397 8900
Bobbie Hilliam (NOMAD) Harry Pardoe
Luther Pendragon	0207 618 9100
Harry Chathli, Claire Norbury, Alexis Gore

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Berry Beumer
2	Reason for the notification
a)	Position/status	Chief Operating Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Kromek Group plc
b)	LEI	N/a
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1p each
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 29.35p   80,000
d)	Aggregated information - Aggregated volume - Price	80,000 Ordinary Shares 29.35p per Ordinary Share
e)	Date of the transaction	24 March 2017
f)	Place of the transaction	London Stock Exchange

About Kromek Group plc

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT").  Using its core CZT technology, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com.

 

END

 

 

DSHOKFDDCBKDFNB